A nationwide recall of two dog and two horse medication lots was issued after glass fibers showed up in retained samples, turning a routine quality check into a safety alert.
Story Snapshot
- American Regent, Inc. Animal Health recalled two lots of Adequan Canine Injection and two lots of Adequan i.m. Injection nationwide.
- The company said the recall was triggered by visible glass fiber material found during testing of internally retained samples.
- The products can cause local irritation, swelling, inflammation, pain, infection, or abscesses if injected with particulate matter.
- The recall covered specific lot numbers, not the entire product line, and the company said no adverse events had been reported at the time.
What Was Recalled
American Regent pulled two lots of Adequan Canine for dogs and two lots of Adequan i.m. for horses from the market. The recalled canine lots were 25011 and 3369, and the horse lots were 24416 and 25265P.
The action reached the consumer level, which means the company warned owners, clinics, distributors, and wholesalers to stop using the products right away.
The recall notice matters because these are injectable medicines, not pills or creams. That raises the stakes fast. The Food and Drug Administration said particulate matter in an intramuscular injectable product may lead to irritation, swelling, inflammation, injection site pain, infection, or abscesses.
That is why even a small foreign material problem can trigger a nationwide pullback before any injuries are reported.
‘Glass Fibers’ Found Inside Dog and Horse Medications Prompt Urgent Nationwide Recall https://t.co/DwIWQV0OxB
— People Pets (@PEOPLEPets) August 7, 2026
Why Glass Fibers Matter
The core issue is not just contamination. It is contamination inside a product meant to go into muscle. Glass fibers can act like tiny splinters in tissue.
The Food and Drug Administration also said American Regent had not received reports of adverse events tied to the recalled lots when the recall was announced. That does not erase the risk. It explains why the company moved early instead of waiting for harm.
The distribution trail shows how widely the products spread before the recall. According to DVM360, the canine lots went out to online pharmacies, distributors, wholesalers, and veterinary practices across the United States, with one lot distributed in 2024 and the other in 2025.
The horse lots followed the same channels, with distribution dates stretching into early 2026. That timeline helps explain why the recall had to be broad, not local.
Why This Recall Stands Out
Recall notices like this usually tell a familiar story: a company catches a problem in testing, then tries to contain it before animals get hurt. That pattern is important because it shows the system working, at least on paper.
The public record here supports the recall itself, the exact lot numbers, and the stated reason. What it does not provide is a full root-cause report explaining where the fibers came from.
That missing detail is what still leaves room for more scrutiny. Was the problem tied to filling, packaging, vial assembly, or some other step? The available sources do not say.
For pet owners and veterinarians, though, the immediate advice is plain: stop using the affected lots, check inventory, and follow the manufacturer’s return or discard instructions. In recalls like this, speed beats debate.
Sources:
foxbusiness.com, usatoday.com, facebook.com
